1. 290 Development and first-in-human characterization of an ICOSL and BAFF bispecific inhibitor AMG 570 for SLE treatment. (April 2019) Authors: Cheng, Laurence E; Hsu, Hailing; Kankam, Martin; Siebers, Nicholas; Stoltz, Randall; Abuqayyas, Lubna; Ertik, Bella; Sullivan, Barbara; Zhou, Lei; Parnes, Jane R Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Interleukin‐21 Receptor Blockade Inhibits Secondary Humoral Responses and Halts the Progression of Preestablished Disease in the (NZB × NZW)F1 Systemic Lupus Erythematosus Model. Issue 10 (23rd September 2015) Authors: Zhang, Ming; Yu, Gang; Chan, Brian; Pearson, Joshua T.; Rathanaswami, Palaniswami; Delaney, John; Ching Lim, Ai; Babcook, John; Hsu, Hailing; Gavin, Marc A. Journal: Arthritis & rheumatology Issue: Volume 67:Issue 10(2015) Page Start: 2723 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prediction of clinical pharmacokinetics of AMG 181, a human anti‐α4β7 monoclonal antibody for treating inflammatory bowel diseases. Issue 1 (9th December 2014) Authors: Li, Hong; Köck, Kathleen; Wisler, John A.; Rees, William A.; Prince, Peter J.; Reynhardt, Kai O.; Hsu, Hailing; Yu, Zhigang; Borie, Dominic C.; Salinger, David H.; Pan, Wei‐Jian Journal: Pharmacology research & perspectives Issue: Volume 3:Issue 1(2015:Feb.) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗